Centauri Therapeutics Limited, an innovative immunotherapy company, has received an additional $5.1 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator). This funding will support the advancement of their lead compound, part of the ABX-01 program, into the first in human clinical trials. With this latest contribution, CARB-X has provided a total of $12.3 million to Centauri since 2019.

The funding will aid in the development of a broad-spectrum antimicrobial candidate specifically designed to combat multidrug-resistant bacterial strains. Selected in March 2025, the candidate aims to target serious Gram-negative bacterial infections, particularly in vulnerable patient populations. Centauri’s proprietary Alphamer platform underpins this innovative approach, enabling a dual mechanism of action. This combines immunotherapeutic effects through complement fixation and phagocytosis with intrinsic antibacterial properties, all within a single molecule.

Dr. Jennifer Schneider, Chief Executive Officer of Centauri Therapeutics, emphasized the importance of CARB-X’s support. “The unwavering scientific and financial support from CARB-X has provided stability to Centauri as a company, expanded understanding of our Alphamer platform, and enabled us to progress the ABX-01 program from discovery through early development,” she stated. “We are thankful for CARB-X and their continued engagement and confidence, allowing us to move closer to delivering a much-needed therapeutic for serious, drug-resistant Gram-negative infections.”

Dr. Erin Duffy, Chief of Research and Development at CARB-X, also expressed pride in supporting Centauri’s journey. “We have been proud to support Centauri, beginning with answering key questions on the approach and continuing with the drug discovery that has led to the lead asset of ABX-01,” she noted. This collaborative effort aims to build a comprehensive dossier to facilitate the transition into human clinical trials.

The funding provided by CARB-X is underpinned by federal funds from the U.S. Department of Health and Human Services (HHS), along with support from Wellcome and Germany’s Federal Ministry of Research, Technology and Space. The content of this announcement reflects the authors’ views and does not necessarily represent the official perspectives of CARB-X or its funders.

As Centauri Therapeutics moves forward, the development of ABX-01 represents a crucial step in addressing the urgent need for effective treatments against drug-resistant infections. The company’s commitment to innovation, combined with significant funding support, positions it well to make substantial contributions to public health in the fight against antibiotic resistance.

Jan Burrell, a 62-year-old grandmother from Stroud, Gloucestershire, faced a life-altering diagnosis of a brain tumour after years of suffering from migraines. Initially attributing her symptoms to aging, Burrell’s sudden personality changes and physical impairments culminated in a seizure that revealed the presence of a tumour the size of a fist.

For years, Jan endured debilitating migraines, often dismissing them as a natural consequence of growing older. In early 2021, she began experiencing significant personality shifts, including increased irritability and forgetfulness. “I started losing my temper,” she recalls. Despite these changes, she did not disclose her concerns to her husband, Steve Burrell.

In February 2022, during a brief walk to the chemist, Jan experienced a seizure that temporarily impaired her vision and speech. She stated, “When it was my turn to speak at the counter there was the sound of only a grunt.” Her husband quickly took her to the emergency department at Gloucestershire Royal Hospital, where further examinations revealed the brain tumour.

“The doctor sat me down and said the words ‘you have a brain tumour’,” Jan described, recalling her immediate reaction of disbelief and fear. Thoughts of her grandchildren flooded her mind, leading to a deep concern about not being able to witness their growth. On May 12, 2022, she underwent a craniotomy at Southmead Hospital, where surgeons successfully removed most of the tumour, which was identified as a slow-growing meningioma.

Following surgery, Jan faced a challenging recovery that included hallucinations due to strong medication. She now lives with quadrantanopia, a condition resulting in permanent vision loss in one quarter of her visual field, necessitating ongoing care from an ophthalmologist. Despite these challenges, Jan found a renewed sense of purpose through creativity.

Determined to leave a legacy for her four-year-old grandson, Finn, Jan wrote a children’s book titled Finn’s Wonderful World. She crafted the story painstakingly, letter by letter, ensuring it was a heartfelt message for Finn should she not be there to share it with him. The process took three years, during which she and Steve saved enough to publish the book.

Every sale of Finn’s Wonderful World supports Brain Tumour Research, a charity that resonates deeply with Jan after her own experience. She expressed, “This book has given me purpose and focus. To see Finn enjoy the story I created for him is the most special gift.”

Letty Greenfield, Community Development Manager at Brain Tumour Research, praised Jan’s efforts, stating,

“Jan’s story is incredibly moving and a powerful reminder of the resilience and creativity that can come out of adversity.”

Greenfield emphasized the importance of awareness and funding for brain tumour research, underscoring the significance of Jan’s contributions.

To purchase Finn’s Wonderful World and support brain tumour research, visit JanBurrellArt on Etsy UK. Jan’s journey from diagnosis to authorship not only highlights the resilience of the human spirit but also serves as a beacon of hope for others facing similar challenges.

As the days grow longer and people bask in the sunshine, many may notice their hair becoming dull and damaged. Factors such as UV exposure, chlorine from swimming pools, and increased heat-styling during summer outings can lead to dry and brittle locks. Fortunately, there are effective and budget-friendly remedies that can help restore hair health without the need for expensive products.

Natural Treatments for Hair Repair

One of the most accessible solutions is using pure aloe vera gel, available at retailers like Holland & Barrett for approximately £4.86. This versatile gel not only alleviates sunburn but also nourishes dry scalps and minimizes split ends. Simply massage the gel into the roots to calm irritation or apply it to the lengths of hair to lock in moisture.

A sweet and simple treatment involves creating a scalp scrub by mixing one tablespoon of sugar with two tablespoons of olive oil. This exfoliating combination effectively removes product buildup and promotes circulation. Gently massaging this mixture into the scalp before shampooing can help eliminate flakes, leaving hair healthier.

For those who enjoy swimming, an apple cider vinegar rinse can be particularly beneficial. Combining one part vinegar with three parts water creates a clarifying rinse that removes chlorine residue, resulting in glossy, vibrant hair. After shampooing, pour the mixture over hair, leave it on for two minutes, and rinse thoroughly to reveal a refreshed look.

Another effective and economical remedy is a DIY conditioning mask. By blending two tablespoons of honey, one mashed banana, and one tablespoon of coconut oil, individuals can create a nourishing treatment. Applying this mask to damp hair and leaving it for 30 minutes before rinsing can effectively tame frizz and restore shine due to the natural enzymes and oils present.

Additional Tips for Hair Care

A final rinse with green tea can also enhance hair shine. Brew two green tea bags in a mug, allow it to cool for 30 minutes, and use the liquid as a final rinse. This method not only adds gloss but also reduces brassiness, providing a more polished appearance.

To protect hair while sleeping, individuals can forgo expensive silk bonnets and instead repurpose a satin dressing gown. By tying hair in a loose topknot and wrapping it with the fabric, this method can help prevent hair breakage overnight.

For an additional layer of care, applying a pea-sized amount of pure glycerin to damp ends before bed can promote moisture retention. Priced around £6 at Superdrug, glycerin is a humectant that draws moisture into the hair strands throughout the night, ensuring a longer-lasting treatment.

These strategies not only address immediate concerns regarding damaged hair but also promote healthier hair practices overall. With minimal investment and readily available ingredients, anyone can give their hair the attention it deserves, turning damaged locks into luscious, revitalized tresses.

Hengrui Pharma has entered into a significant agreement with GSK to develop up to 12 innovative medicines across various therapeutic areas, including respiratory conditions, immunology, inflammation, and oncology. This partnership is intended to bolster Hengrui’s globalisation strategy while providing GSK with substantial growth opportunities that extend beyond 2031.

As part of the agreement, GSK will pay an upfront fee of $500 million, which includes the licensing for the phosphodiesterase (PDE)3/4 programme. The collaboration has the potential to generate nearly $12 billion in future success-based payments to Hengrui Pharma, assuming all programmes are successfully optioned and milestones are achieved. Furthermore, Hengrui Pharma will receive tiered royalties on worldwide product net sales, with specific regional exclusions.

Details of the Collaboration

A focal point of the partnership is the worldwide licence for HRS-9821, a PDE3/4 inhibitor currently in clinical development for chronic obstructive pulmonary disease (COPD). This programme aligns with GSK’s objective to meet the needs of a diverse range of COPD patients, particularly those experiencing ongoing dyspnoea or those who are less likely to be prescribed inhaled corticosteroids or biologics. Initial trials have indicated that HRS-9821 exhibits positive anti-inflammatory and bronchodilation effects, and its potential for a dry-powder inhaler formulation could seamlessly integrate with GSK’s existing inhaled portfolio.

Frank Jiang, Executive Vice-President and Chief Strategy Officer at Hengrui Pharma, expressed enthusiasm about the collaboration, stating, “GSK brings additional research and development expertise, a robust global clinical network and broad regulatory capabilities that will accelerate our PDE3/4 inhibitor as well as an array of other innovative therapy programmes to overseas markets, potentially delivering breakthrough treatments to patients globally.”

Beyond HRS-9821, the collaboration encompasses up to 11 additional programmes. Hengrui Pharma will lead the development of these projects up to Phase I trials. Following this, GSK may choose to continue development and commercialisation on a global scale, excluding mainland China, the Macau Special Administrative Region, Hong Kong Special Administrative Region, and Taiwan.

Strategic Implications

This expansive collaboration is structured to expedite the development of innovative medicines, leveraging GSK’s extensive expertise and global reach alongside Hengrui Pharma’s capabilities in discovery and clinical evaluation. The licensing of HRS-9821 is subject to customary regulatory approvals, including compliance with the Hart-Scott-Rodino Act in the United States.

In a related development, in March 2025, MSD entered into an exclusive licence agreement with Hengrui Pharma for the investigational oral small-molecule lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. This agreement further underscores Hengrui Pharma’s commitment to advancing its pipeline of innovative therapeutic solutions.

The collaboration with GSK represents a pivotal move for Hengrui Pharma as it seeks to expand its presence in the global pharmaceutical market while enhancing GSK’s portfolio with promising new treatments for serious health conditions.